CWT Versus AT on Selected Cardiovascular Indices and Functional Capacity in Patients With Ischemic Cardiomyopathy.

February 5, 2024 updated by: Samira Shukrey Shaffik Eshak, Cairo University

Circuit Weight Versus Aerobic Training on Selected Cardiovascular Indices and Functional Capacity in Patients With Ischemic Cardiomyopathy.

To compare between the effect of circuit weight and aerobic training on selected cardiovascular indices and functional capacity in patients with ischemic cardiomyopathy.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Ischemic cardiomyopathy (ICM) is a term that refers to the heart's decreased ability to pump blood properly due to myocardial damage brought upon by ischemia. Ischemic cardiomyopathy has a spectrum of clinical changes which eventually leads to congestive heart failure (CHF). Initially, there is a reversible loss of cardiac contractile function because of decreased oxygen supply to the heart muscle; however, when there is ischemia for a prolonged period, there is irreversible cardiac muscle damage resulting in cardiac remodeling. Remodeling is primarily achieved by myocardial fibrosis which results in decreased cardiac function, arrhythmia, and possible cardiac conduction system impairment. In ischemic cardiomyopathy, there is a significant impairment of the left ventricular systolic function, with a left ventricular ejection fraction (LVEF) less than 40% (Bhandari et al., 2021).

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Sixty male patients with ischemic cardiomyopathy as a result of a recent acute myocardial infarction event (≤2 months) with 40%<LVEF<50%.
  • They are functionally classified as class II according to New York Heart Association (NYHA).
  • Their age will be ranged from 45 to 55 years old.
  • Their BMI will be ranged from 25 to 29.9 kg/m².
  • They will have good mentality.

Exclusion Criteria:

  • Recurrent coronary heart disease.
  • Severe valvular diseases.
  • Underlying pulmonary disease (aspiration pneumonia, chronic obstructive pulmonary disease, pneumothorax, etc.).
  • Inability to ambulate owing to physical problems (paresis induced by cerebral stroke, spinal cord injury, amputation, severe pain, dyspnea, etc.).
  • muskloskletal problems (e.g. severe osteoarthritis or ankylosing spondylitis).
  • Impaired cognitive function (vascular dementia, Alzheimer's dementia, other psychological disease, etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Circuit weight group
Diagnostic test: Circuit weight versus aerobic training

Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)

B- Aerobic training:

This mode of exercise will be conducted for study group B as follows:

Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.

Frequency: Three times / week (Nishi et al., 2011).

C-Traditional medical treatment:

This treatment will be conducted for all group A, B and C.
Experimental: Aerobic group
Diagnostic test: Circuit weight versus aerobic training

Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)

B- Aerobic training:

This mode of exercise will be conducted for study group B as follows:

Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.

Frequency: Three times / week (Nishi et al., 2011).

C-Traditional medical treatment:

This treatment will be conducted for all group A, B and C.
Experimental: Control Group
Diagnostic test: Circuit weight versus aerobic training

Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)

B- Aerobic training:

This mode of exercise will be conducted for study group B as follows:

Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.

Frequency: Three times / week (Nishi et al., 2011).

C-Traditional medical treatment:

This treatment will be conducted for all group A, B and C.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ejection fraction
Time Frame: 2 months
Will be measured by precentge
2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure
Time Frame: 2 months
Will be measured by mmhg
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 8, 2024

Primary Completion (Estimated)

March 5, 2024

Study Completion (Estimated)

March 8, 2024

Study Registration Dates

First Submitted

December 10, 2022

First Submitted That Met QC Criteria

December 29, 2022

First Posted (Actual)

January 9, 2023

Study Record Updates

Last Update Posted (Estimated)

February 6, 2024

Last Update Submitted That Met QC Criteria

February 5, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Cw versus AT in cardiomyopathy

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ischemic Cardiomyopathy

Clinical Trials on Circuit weight versus aerobic training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe